All News

elderly hands

A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology

Jiha Lee, MD

A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional structures.

Read Article
EULAR19.abstract.jpg (keep)

EULAR 2026: Industry Press Releases

Jack Cush, MD

Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.

Read Article
manpower.cliff.shortage

Rheumatology Shortage Cliff in Australia & USA

Jack Cush, MD

Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.

Read Article
RheumNow Podcast square

Count Your Telangiectasias (5.29.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and missed quiz questions.

Read Article
APR Safety Video Cover

Safety of Biologics and Novel Agents

Jack Cush, MD

Dr. Jack Cush reviews safety of biologics and novel agents.

Read Article
RheumNow Podcast square

Quiz Talk (5.22.2026)

Jack Cush, MD

Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.

Read Article
lupus.skinbx.jpg

A Role for Plasmacytoid Dendritic Cells in Lupus

Jack Cush, MD

Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon, drive systemic lupus erythematosus and cutaneous lupus erythematosus. A recent comprehensive review synthesizes the available data on pDCs, and, importantly, what we still don't know.

Read Article
Does #Rx w #immunesuppression w #antifibrotic Help #SARD-ILD? YES. N=40 SARD-ILD, 1/2 w UIP pattern Use of #IS w #antifibrotic pt group had better survival Small N and ?channeling bias But interesting results TAke home : Use IS + antifibrotic #EULAR2026 #POS0530 @RheumNow https://t.co/tfxVVw27jJ

Links:

Janet Pope Janetbirdope ( View Tweet)
Not all "difficult-to-treat" #PsA definitions are equal. Real-world DEPAR cohort (n=885): 20% met GRAPPA complex-to-manage vs only 4% EULAR difficult-to-manage criteria. Definition choice determines who gets identified, and who gets left behind. @RheumNow #EULAR2026 POS0446

Jiha Lee JihaRheum ( View Tweet)

#EULAR2026 POS0440 1-Year Open Label Extension Study of 6-monthly Inebilizumab, a CD19 depleter in #IgG4 disease: -No flare in INEB group; 6% flare in PBO-INEB -10.9% serious infections -1 pt discontinued due to low IgG Interested to see longer-term safety data @RheumNow https://t.co/PPUw81T8DZ

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Prof. Pedro Machado shares this important slide on a quick guide to #vaccination in patients w/ RMDs highlighting which vaccines are universally indicated, accdg to epidemiologic risk and w/ CIs. #EULAR2026 @RheumNow https://t.co/JmTSC1uaph

Links:

sheila RHEUMarampa ( View Tweet)
#EULAR2026 General Assembly is ON! Record-breaking 5'705 abstracts from 102 countries 187 scientific sessions ahead @rheumnow https://t.co/0kAqND11L7

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Congratulations to Professor Dennis McGonagle for being awarded the prestigious Heberden Oration Award at the 2026 British Society for Rheumatology (BSR) Conference. https://t.co/TOG5Y9tNrW https://t.co/3aumO6Z3A9

Links:

Dr. John Cush RheumNow ( View Tweet)
“Common sense in matters medical is rare, and is usually in inverse ratio to the degree of education.” – Sir William Osler

Dr. John Cush RheumNow ( View Tweet)

Join the global rheumatology community following RheumNow at #EULAR2026 ✔️ Trusted faculty voices ✔️ Fast, curated insights ✔️ Clinically relevant takeaways This is where rheumatology meets real-world practice. https://t.co/Hb88ZCP58P
Dr. John Cush RheumNow ( View Tweet)
RHEUM SURVEY> Per 2024 EULAR Guidelines, an active RA pt on MTX who fails a 1st TNFi, should next change to ?

Dr. John Cush RheumNow ( View Tweet)

RHEUM SURVEY> Per 2024 EULAR Guidelines, an active RA pt on MTX who fails a 1st TNFi, should next change to ?

Dr. John Cush RheumNow ( View Tweet)

Quiz Talk (5.22.2026) Dr. Jack Cush talks of birthdays, quizzes, and journal articles this week on the podcast. https://t.co/LwX0XxgPhn https://t.co/4uVTQo6NLG

Links:

Dr. John Cush RheumNow ( View Tweet)
BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6. This head-to-head trial demonstrates that at week 16, bimekizumab (BKZ) yielded superior ACR50 https://t.co/VVBaNdWIuQ
Dr. John Cush RheumNow ( View Tweet)
Can’t attend #EULAR2026? You won’t miss a thing. RheumNow delivers: 📬 Daily summaries 🎥 Interviews 📊 Key data highlights Follow https://t.co/V10S4oVFsv June 3–6. https://t.co/7Xdj94eFu4

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×